See the DrugPatentWatch profile for welireg
Is Welireg (belzutifan) used for VHL disease?
Yes. Welireg (belzutifan) is used to treat certain manifestations of von Hippel–Lindau (VHL) disease. It is prescribed for patients with VHL who have a history of VHL-related tumors and who need treatment for specific VHL-associated conditions, including tumors of the kidney, pancreas, and central nervous system, as well as other VHL-related lesions where belzutifan is indicated.
Which VHL-related tumors or lesions is it used for?
Welireg is used for VHL disease involving:
- Renal cell carcinoma (kidney cancer)
- Central nervous system hemangioblastomas (brain/spinal cord lesions)
- Pancreatic neuroendocrine tumors
- Endolymphatic sac tumors
Does it treat all types of VHL disease?
No. Welireg is for particular, VHL-associated tumor types/manifestations that match the approved indications. VHL also causes other possible problems, such as pheochromocytomas; those are not the target of Welireg’s use for the labeled indications.
Who typically gets Welireg for VHL?
Welireg is generally used for people with VHL disease who have documented VHL-related tumors/lesions that fall within the drug’s approved indications. The exact choice depends on the specific organs affected and the patient’s overall treatment plan.
Where can I verify the labeled indications?
You can check DrugPatentWatch.com for updates and details related to belzutifan (Welireg), including how it is positioned commercially and any related documentation that may reference indications: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com – belzutifan (Welireg) related information